Eugenie S Kleinerman

List of Publications by Year
in descending order

97 papers	5,155 citations	101543 36 h-index	95266 68 g-index
99 all docs	99 docs citations	99 times ranked	5225 citing authors

#	Article	IF	Citations
1	Short-Term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients. Journal of Adolescent and Young Adult Oncology, 2022, 11, 320-322.	1.3	6
2	Bempegaldesleukin (BEMPEG ; NKTR â€214) efficacy as a single agent and in combination with checkpointâ€inhibitor therapy in mouse models of osteosarcoma. International Journal of Cancer, 2021, 148, 1928-1937.	5.1	8
3	Assessment of drug transporters involved in the urinary secretion of [99mTc]dimercaptosuccinic acid. Nuclear Medicine and Biology, 2021, 94-95, 92-97.	0.6	1
4	Up-regulation of pro-angiogenic molecules and events does not relate with an angiogenic switch in metastatic osteosarcoma cells but to cell survival features. Apoptosis: an International Journal on Programmed Cell Death, 2021, 26, 447-459.	4.9	5
5	Exercise Inhibits Doxorubicin-Induced Damage to Cardiac Vessels and Activation of Hippo/YAP-Mediated Apoptosis. Cancers, 2021, 13, 2740.	3.7	17
6	Exercise intervention decreases acute and late doxorubicinâ€induced cardiotoxicity. Cancer Medicine, 2021, 10, 7572-7584.	2.8	17
7	Meet the Editorial Board Member. Cardiovascular & Hematological Disorders Drug Targets, 2021, 21, 87-87.	0.7	0
8	Prognostic Value of Cell-Surface Vimentin-Positive CTCs in Pediatric Sarcomas. Frontiers in Oncology, 2021, 11, 760267.	2.8	5
9	The Fas/FasL Signaling Pathway: Its Role in the Metastatic Process and as a Target for Treating Osteosarcoma Lung Metastases. Advances in Experimental Medicine and Biology, 2020, 1258, 177-187.	1.6	9
10	Exosomes: Dynamic Mediators of Extracellular Communication in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1258, 189-197.	1.6	16
11	[131I]MIBG exports via MRP transporters and inhibition of the MRP transporters improves accumulation of [131I]MIBG in neuroblastoma. Nuclear Medicine and Biology, 2020, 90-91, 49-54.	0.6	6
12	Neuronal Repressor REST Controls Ewing Sarcoma Growth and Metastasis by Affecting Vascular Pericyte Coverage and Vessel Perfusion. Cancers, 2020, 12, 1405.	3.7	4
13	Knock down of Fas-Associated Protein with Death Domain (FADD) Sensitizes Osteosarcoma to TNFÎ±-induced Cell Death. Journal of Cancer, 2020, 11, 1657-1667.	2.5	8
14	Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103⁺conventional dendritic cells. , 2020, 8, e000474.		57
15	Exosomal communication by metastatic osteosarcoma cells modulates alveolar macrophages to an M2 tumor-promoting phenotype and inhibits tumoricidal functions. OncoImmunology, 2020, 9, 1747677.	4.6	75
16	Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention. Advances in Experimental Medicine and Biology, 2020, 1257, 181-192.	1.6	104
17	Vascular modulation through exercise improves chemotherapy efficacy in Ewing sarcoma. Pediatric Blood and Cancer, 2019, 66, e27835.	1.5	32
18	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clinical Cancer Research, 2019, 25, 3802-3810.	7.0	42

#	Article	IF	Citations
19	Short-Term Changes in Cardiac Function in Osteosarcoma Patients Receiving Anthracyclines. Journal of Adolescent and Young Adult Oncology, 2019, 8, 385-386.	1.3	4
20	Analysis of HSP27 and the Autophagy Marker LC3B+ Puncta Following Preoperative Chemotherapy Identifies High-Risk Osteosarcoma Patients. Molecular Cancer Therapeutics, 2018, 17, 1315-1323.	4.1	13
21	Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity. Journal of Pediatric Hematology/Oncology, 2018, 40, 208-215.	0.6	32
22	miR-20a Regulates FAS Expression in Osteosarcoma Cells by Modulating <i>FAS</i> Promoter Activity and Can be Therapeutically Targeted to Inhibit Lung Metastases. Molecular Cancer Therapeutics, 2018, 17, 130-139.	4.1	12
23	Diet and exercise interventions for pediatric cancer patients during therapy: tipping the scales for better outcomes. Pediatric Research, 2018, 83, 50-56.	2.3	21
24	Using the Spleen as an<i>In Vivo</i>Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with<i>Î±</i>-PD-L1. Sarcoma, 2018, 2018, 1-13.	1.3	24
25	Aerosol Gemcitabine after Amputation Inhibits Osteosarcoma Lung Metastases but Not Wound Healing. Sarcoma, 2018, 2018, 1-12.	1.3	3
26	Antiâ€PDâ€1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Medicine, 2018, 7, 2654-2664.	2.8	126
27	Abstract 3008: Effect of exercise on acute and late onset Doxorubicin-induced cardiotoxicity. , 2018, , .		3
28	Phosphorylated heat shock protein 27 as a potential biomarker to predict the role of chemotherapy-induced autophagy in osteosarcoma response to therapy. Oncotarget, 2018, 9, 1602-1616.	1.8	15
29	Induction of NKG2D Ligands on Solid Tumors Requires Tumor-Specific CD8+ T Cells and Histone Acetyltransferases. Cancer Immunology Research, 2017, 5, 300-311.	3.4	20
30	Osteosarcoma Overview. Rheumatology and Therapy, 2017, 4, 25-43.	2.3	317
31	Effect of entinostat on NK cell-mediated cytotoxicity against osteosarcoma cells and osteosarcoma lung metastasis. OncoImmunology, 2017, 6, e1333214.	4.6	32
32	BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8065-8070.	7.1	26
33	Hes4: A potential prognostic biomarker for newly diagnosed patients with highâ€grade osteosarcoma. Pediatric Blood and Cancer, 2017, 64, e26318.	1.5	15
34	Maximum benefit of chemotherapy for osteosarcoma achievedâ€"what are the next steps?. Lancet Oncology, The, 2016, 17, 1340-1342.	10.7	24
35	Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 <i>In Vivo</i>. Clinical Cancer Research, 2016, 22, 3876-3883.	7.0	15
36	The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells. Pharmaceutical Research, 2015, 32, 779-792.	3.5	86

#	Article	IF	Citations
37	Blocking SDF-1Î±/CXCR4 Downregulates PDGF-B and Inhibits Bone Marrowâ€“Derived Pericyte Differentiation and Tumor Vascular Expansion in Ewing Tumors. Molecular Cancer Therapeutics, 2014, 13, 483-491.	4.1	37
38	Aerosol interleukinâ€2 induces natural killer cell proliferation in the lung and combination therapy improves the survival of mice with osteosarcoma lung metastasis. Pediatric Blood and Cancer, 2014, 61, 1362-1368.	1.5	29
39	EWSâ€FLIâ€1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology. Cancer, 2014, 120, 579-588.	4.1	21
40	Natural killer cell therapy and aerosol interleukinâ€2 for the treatment of osteosarcoma lung metastasis. Pediatric Blood and Cancer, 2014, 61, 618-626.	1.5	35
41	Participation of the Fas/FasL Signaling Pathway and the Lung Microenvironment in the Development of Osteosarcoma Lung Metastases. Advances in Experimental Medicine and Biology, 2014, 804, 203-217.	1.6	22
42	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience. Oncoscience, 2014, 1, 522-530.	2.2	7
43	Expression of câ€FLIP in pulmonary metastases in osteosarcoma patients and human xenografts. Pediatric Blood and Cancer, 2013, 60, 575-579.	1.5	19
44	The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases. Current Cancer Drug Targets, 2013, 13, 411-422.	1.6	41
45	miR-20a Encoded by the miR-17â€“92 Cluster Increases the Metastatic Potential of Osteosarcoma Cells by Regulating Fas Expression. Cancer Research, 2012, 72, 908-916.	0.9	162
46	Genetically Modified T cells Targeting Interleukin-11 Receptor Î±-Chain Kill Human Osteosarcoma Cells and Induce the Regression of Established Osteosarcoma Lung Metastases. Cancer Research, 2012, 72, 271-281.	0.9	103
47	CAPERâ€Î± alternative splicing regulates the expression of vascular endothelial growth factor₁₆₅ in Ewing sarcoma cells. Cancer, 2012, 118, 2106-2116.	4.1	45
48	Epigenetic Regulation of Apoptosis and Cell Cycle in Osteosarcoma. Sarcoma, 2011, 2011, 1-5.	1.3	22
49	SDF-1Î± Induces PDGF-B Expression and the Differentiation of Bone Marrow Cells into Pericytes. Molecular Cancer Research, 2011, 9, 1462-1470.	3.4	31
50	Delta-like ligand 4â€“Notch signaling regulates bone marrowâ€“derived pericyte/vascular smooth muscle cell formation. Blood, 2011, 117, 719-726.	1.4	36
51	Bone marrow cells participate in tumor vessel formation that supports the growth of Ewingâ€™s sarcoma in the lung. Angiogenesis, 2011, 14, 125-133.	7.2	12
52	Effect of the histone deacetylase inhibitor SNDXâ€275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases. Cancer, 2011, 117, 3457-3467.	4.1	30
53	Tumor Vessel Development and Expansion in Ewing's Sarcoma: A Review of the Vasculogenesis Process and Clinical Trials with Vascular-Targeting Agents. Sarcoma, 2011, 2011, 1-7.	1.3	20
54	Abstract 5335: The histone deacetylase inhibitor MS-275 sensitizes osteosarcoma cells and osteosarcoma lung metastases to FasL-induced cell death by the downregulation c-FLIP. , 2011, , .		2

#	Article	IF	Citations
55	Vasculogenesis Driven by Bone Marrow-Derived Cells Is Essential for Growth of Ewing's Sarcomas. Cancer Research, 2010, 70, 1334-1343.	0.9	23
56	Delta-Like Ligand 4 Plays a Critical Role in Pericyte/Vascular Smooth Muscle Cell Formation during Vasculogenesis and Tumor Vessel Expansion in Ewing's Sarcoma. Clinical Cancer Research, 2010, 16, 848-856.	7.0	34
57	Aerosol Gemcitabine: Preclinical Safety and<i>In Vivo</i>Antitumor Activity in Osteosarcoma-Bearing Dogs. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 197-206.	1.4	39
58	Aerosol Therapy for the Treatment of Osteosarcoma Lung Metastases: Targeting the Fas/FasL Pathway and Rationale for the Use of Gemcitabine. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2010, 23, 189-196.	1.4	36
59	Murine bone marrowâ€“derived mesenchymal stem cells as vehicles for interleukinâ€12 gene delivery into Ewing sarcoma tumors. Cancer, 2009, 115, 13-22.	4.1	68
60	Fas Expression in Metastatic Osteosarcoma Cells Is Not Regulated by CpG Island Methylation. Oncology Research, 2009, 18, 31-39.	1.5	9
61	The Role of Fas/FasL in the Metastatic Potential of Osteosarcoma and Targeting this Pathway for the Treatment of Osteosarcoma Lung Metastases. Cancer Treatment and Research, 2009, 152, 497-508.	0.5	37
62	VEGF₁₆₅ Promotes the Osteolytic Bone Destruction of Ewing's Sarcoma Tumors by Upregulating RANKL. Oncology Research, 2009, 18, 117-125.	1.5	26
63	VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewingâ€™s sarcoma vasculature. Angiogenesis, 2008, 11, 257-267.	7.2	24
64	Stromal cellâ€derived factorâ€1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor. International Journal of Cancer, 2008, 123, 831-837.	5.1	47
65	Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survivalâ€"A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2008, 26, 633-638.	1.6	666
66	Bone Marrow Subsets Differentiate into Endothelial Cells and Pericytes Contributing to Ewing's Tumor Vessels. Molecular Cancer Research, 2008, 6, 929-936.	3.4	46
67	Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma. Molecular Cancer Therapeutics, 2008, 7, 1807-1816.	4.1	54
68	VEGF165 is necessary to the metastatic potential of Fas(-) osteosarcoma cells but will not rescue the Fas(+) cells. Journal of Experimental Therapeutics and Oncology, 2008, 7, 89-97.	0.5	7
69	VEGF165, but not VEGF189, Stimulates Vasculogenesis and Bone Marrow Cell Migration into Ewing's Sarcoma Tumors <i>In vivo</i>. Molecular Cancer Research, 2007, 5, 1125-1132.	3.4	30
70	Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Antiâ€“Vascular Endothelial Growth Factor Receptor-2 Therapy. Clinical Cancer Research, 2007, 13, 4867-4873.	7.0	40
71	Fas-Negative Osteosarcoma Tumor Cells Are Selected during Metastasis to the Lungs: The Role of the Fas Pathway in the Metastatic Process of Osteosarcoma. Molecular Cancer Research, 2007, 5, 991-999.	3.4	63
72	Corruption of the Fas Pathway Delays the Pulmonary Clearance of Murine Osteosarcoma Cells, Enhances Their Metastatic Potential, and Reduces the Effect of Aerosol Gemcitabine. Clinical Cancer Research, 2007, 13, 4503-4510.	7.0	69

#	Article	IF	Citations
73	Early Lymphocyte Recovery as a Prognostic Indicator for High-risk Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2007, 29, 48-52.	0.6	62
74	Exploratory Analysis of Fas Gene Polymorphisms in Pediatric Osteosarcoma Patients. Journal of Pediatric Hematology/Oncology, 2007, 29, 815-821.	0.6	35
75	Expression of granulocyteâ€colonyâ€stimulating factor and its receptor in human Ewing sarcoma cells and patient tumor specimens. Cancer, 2007, 110, 1568-1577.	4.1	36
76	Intranasal interleukin-12 gene therapy enhanced the activity of ifosfamide against osteosarcoma lung metastases. Cancer, 2006, 106, 1382-1388.	4.1	44
77	Production of VEGF165 by Ewing's sarcoma cells induces vasculogenesis and the incorporation of CD34+ stem cells into the expanding tumor vasculature. International Journal of Cancer, 2006, 119, 839-846.	5.1	42
78	Fas Expression in Lung Metastasis From Osteosarcoma Patients. Journal of Pediatric Hematology/Oncology, 2005, 27, 611-615.	0.6	42
79	Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. International Journal of Cancer, 2005, 116, 458-463.	5.1	90
80	Association of Î± v Î² 3 integrin expression with the metastatic potential and migratory and chemotactic ability of human osteosarcoma cells. Clinical and Experimental Metastasis, 2005, 21, 747-753.	3.3	41
81	A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model. Clinical Cancer Research, 2005, 11, 2662-2669.	7.0	111
82	Interleukin-12 Up-Regulates Fas Expression in Human Osteosarcoma and Ewing's Sarcoma Cells by Enhancing Its Promoter Activity. Molecular Cancer Research, 2005, 3, 685-692.	3.4	35
83	Osteosarcoma: A Randomized, Prospective Trial of the Addition of Ifosfamide and/or Muramyl Tripeptide to Cisplatin, Doxorubicin, and High-Dose Methotrexate. Journal of Clinical Oncology, 2005, 23, 2004-2011.	1.6	649
84	Interleukin-12 Enhances the Sensitivity of Human Osteosarcoma Cells to 4-Hydroperoxycyclophosphamide by a Mechanism Involving the Fas/Fas-Ligand Pathway. Clinical Cancer Research, 2004, 10, 777-783.	7.0	21
85	Increased Fas Expression Reduces the Metastatic Potential of Human Osteosarcoma Cells. Clinical Cancer Research, 2004, 10, 8114-8119.	7.0	86
86	Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clinical Cancer Research, 2003, 9, 3462-8.	7.0	51
87	E1A gene therapy inhibits angiogenesis in a Ewing's sarcoma animal model. Molecular Cancer Therapeutics, 2003, 2, 1313-9.	4.1	34
88	Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Therapy, 2002, 9, 260-266.	4.6	57
89	Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncology Reports, 2002, 9, 823-7.	2.6	57
90	Vasculogenesis Plays a Role in the Growth of Ewing's Sarcoma in Vivo. Clinical Cancer Research, 2002, 8, 3622-7.	7.0	53

#	Article	IF	Citations
91	Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEIâ€“ p53 complexes. Cancer Gene Therapy, 2001, 8, 619-627.	4.6	70
92	9â€Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice. Annals of the New York Academy of Sciences, 2000, 922, 151-163.	3.8	41
93	A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clinical and Experimental Metastasis, 1999, 17, 501-506.	3.3	126
94	ImmTher, a lipophilic disaccharide derivative of muramyl dipeptide, up-regulates specific monocyte cytokine genes and activates monocyte-mediated tumoricidal activity. Cancer Immunology, Immunotherapy, 1999, 48, 312-320.	4.2	23
95	Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1995, 18, 93-99.	1.3	110
96	Mechanisms of Kupffer cell cytotoxicity in vitro against the syngeneic murine colon adenocarcinoma line MCA26. Journal of Leukocyte Biology, 1993, 53, 715-721.	3.3	26
97	Metastatic epidural osteosarcoma initially diagnosed as cisplatin neuropathy. Journal of Neuro-Oncology, 1986, 4, 165-167.	2.9	2